LIVIVO - Search results -

Search results

Result 1 - 10 of total 125

Search options

Article ; Online: The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma.

De Corso, Eugenio / D'Amato, Maria / Carpagnano, Giovanna Elisiana / Pelaia, Girolamo / Bonini, Matteo

2023 Volume 23, Issue 5, Page(s) 237–248

Abstract: ... underlying mechanisms (e.g., type-2 inflammation), which sustain symptoms and poor comorbid patient quality ...

Abstract	Purpose of review: The present review aims to systematically assess published data to elucidate benralizumab efficacy on nasal outcomes in comorbid patients. Recent findings: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the nasal cavity often associated with severe asthma (SA), contributing to a global disease burden in asthmatics. The two pathologies share common underlying mechanisms (e.g., type-2 inflammation), which sustain symptoms and poor comorbid patient quality of life. Therefore, it is of primary importance to identify the correct therapeutic option in order to achieve the optimal management of patients affected by both pathologies. Benralizumab is a humanized monoclonal antibody directed at the α subunit of the interleukin-5 receptor (IL-5Rα) approved for the treatment of severe eosinophilic asthma. Increasing body of literature provides data on its efficacy also on CRSwNP in the comorbid SA patient. Based on the data described in this review, when benralizumab is administered to comorbid patients, it does not only control severe asthma but also improves CRSwNP clinical outcomes, although we need further studies to add stronger evidence and to improve the correct pheno-endotyping of the comorbid patient.
MeSH term(s)	Humans ; Nasal Polyps/complications ; Nasal Polyps/drug therapy ; Quality of Life ; Asthma/complications ; Asthma/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Chronic Disease ; Sinusitis/complications ; Sinusitis/drug therapy ; Sinusitis/epidemiology
Chemical Substances	benralizumab (71492GE1FX) ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2023-03-30
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057370-4
ISSN	1534-6315 ; 1529-7322
ISSN (online)	1534-6315
ISSN	1529-7322
DOI	10.1007/s11882-023-01074-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5548: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: The eye may be the spy of injury related to NIV interface and prone positioning.

Pierucci, P / de Candia, M L / Marzullo, A / Mele, F / Introna, F / Agrisani, C / Ingoglia, G / Gregoretti, C / Carpagnano, G E

Pulmonology

2022 Volume 30, Issue 2, Page(s) 192–194

MeSH term(s)	Humans ; Prone Position ; Respiration, Artificial ; Respiratory Distress Syndrome
Language	English
Publishing date	2022-07-05
Publishing country	Spain
Document type	Letter
ZDB-ID	3009651-0
ISSN	2531-0437 ; 2531-0429
ISSN (online)	2531-0437
ISSN	2531-0429
DOI	10.1016/j.pulmoe.2022.05.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection.

Bavaro, D F / Diella, L / Solimando, A G / Cicco, S / Buonamico, E / Stasi, C / Ciannarella, M / Marrone, M / Carpagnano, F / Resta, O / Carpagnano, G E / Palmieri, V O / Vacca, A / Dell'Aera, M / Dell'Erba, A / Migliore, G / Aricò, M / Saracino, A

Pathogens and global health

2022 Volume 116, Issue 5, Page(s) 297–304

Abstract: The early administration of anti-SARS-CoV-2 monoclonal antibodies (mAb) could decrease the risk of severe disease and the need of inpatients care. Herein, our clinical experience with Bamlanivimab/Etesevimab for the treatment of early SARS-CoV-2 ... ...

Abstract	The early administration of anti-SARS-CoV-2 monoclonal antibodies (mAb) could decrease the risk of severe disease and the need of inpatients care. Herein, our clinical experience with Bamlanivimab/Etesevimab for the treatment of early SARS-CoV-2 infection through an outpatient service was described. Patients with confirmed COVID-19 were selected by General Practitioners (GPs) if eligible to mAb administration, according to manufacturer and AIFA (Agenzia-Italiana-del-Farmaco) criteria. If suitability was confirmed by the Multidisciplinary Team, the patient was evaluated within the next 48-72 hours. Then, all patients underwent a medical evaluation, followed by mAb infusion or hospitalization if the medical condition had worsened. Overall, from March 29th to June 4th, 2021, 106 patients with confirmed COVID-19 were identified by GPs; 26 were considered not eligible and then excluded, while 9 refused treatment. Among the 71 remaining, 6 were not treated because of worsening of symptoms soon after selection. Finally, 65 received mAb therapy. All treated patients survived. However, 2/65 developed adverse events (allergic reaction and atrial fibrillation, respectively) and 6/65 needed hospitalization. By performing univariate logistic regression analysis, diabetes was the only risk factor for hospitalization after mAb administration [aOR = 9.34, 95%CI = 1.31-66.49,
MeSH term(s)	Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19/drug therapy ; Humans ; Outpatients ; SARS-CoV-2
Chemical Substances	Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; Antibodies, Viral ; bamlanivimab (45I6OFJ8QH) ; etesevimab (N7Q9NLF11I)
Language	English
Publishing date	2022-02-09
Publishing country	England
Document type	Journal Article
ZDB-ID	2625162-0
ISSN	2047-7732 ; 2047-7724
ISSN (online)	2047-7732
ISSN	2047-7724
DOI	10.1080/20477724.2021.2024030
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.196: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey.

Crimi, Claudia / Calabrese, Cecilia / D'Amato, Maria / Blasi, Francesco / Canonica, Giorgio Walter / Guida, Giuseppe / Heffler, Enrico / Paggiaro, Pierluigi / Carpagnano, Giovanna Elisiana

ERJ open research

2023 Volume 9, Issue 6

Abstract: Patients with severe asthma perceive beneficial effects of biologics and good self-reported adherence to treatment, even when self-administered at ... ...

Abstract	Patients with severe asthma perceive beneficial effects of biologics and good self-reported adherence to treatment, even when self-administered at home
Language	English
Publishing date	2023-11-13
Publishing country	England
Document type	Journal Article
ZDB-ID	2827830-6
ISSN	2312-0541
ISSN	2312-0541
DOI	10.1183/23120541.00560-2023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management.

Carpagnano, Giovanna Elisiana / Scioscia, Giulia / Buonamico, Enrico / Lacedonia, Donato / Diaferia, Fabrizio / Capozza, Elena / Lepore, Giorgia / Resta, Onofrio / Foschino Barbaro, Maria Pia

Multidisciplinary respiratory medicine

2022 Volume 17, Issue 1, Page(s) 797

Abstract: Background: Dupilumab is a humanized monoclonal antibody targeting the IL4/IL13 signaling pathway, already used for atopic dermatitis and chronic rhinitis with nasal polyps, recently approved for severe type-2 asthma. Its efficacy has been demonstrated ... ...

Abstract	Background: Dupilumab is a humanized monoclonal antibody targeting the IL4/IL13 signaling pathway, already used for atopic dermatitis and chronic rhinitis with nasal polyps, recently approved for severe type-2 asthma. Its efficacy has been demonstrated in randomized control trials. The aim of our study is to evaluate possible early clinical improvement and type 2 biomarkers modifications in severe asthmatic patients treated with dupilumab in a real-life setting. Methods: We included 12 patients with severe, uncontrolled asthma and dupilumab was chosen if there was at least one evidence of blood eosinophils> 150 cells/ml and/or FeNO>25 ppb during last year. Recent blood eosinophil count report, assessment through ACT, FeNO test and spirometry were performed at baseline and after 3 months of treatment. We calculated also the number of patients achieving a minimal, yet clinically relevant difference in FEV Results: After three months of treatment with dupilumab, ACT had a significant improvement (mean ACT pre 13.25±4.65 Conclusions: In RCTs performed during clinical development program dupilumab showed an early efficacy in increasing FEV
Language	English
Publishing date	2022-02-04
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2677839-7
ISSN	2049-6958 ; 1828-695X
ISSN (online)	2049-6958
ISSN	1828-695X
DOI	10.4081/mrm.2022.797
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Metabolic Bone Diseases in the Pediatric Population.

Testini, Valentina / Eusebi, Laura / Tupputi, Umberto / Carpagnano, Francesca Anna / Bartelli, Francesco / Guglielmi, Giuseppe

Seminars in musculoskeletal radiology

2021 Volume 25, Issue 1, Page(s) 94–104

Abstract: ... in recent years in the diagnosis of metabolic bone diseases (e.g., osteogenesis imperfecta ...

Abstract	Bone plays an important role in regulating mineral balance in response to physiologic needs. In addition, bone is subject to a continuous remodeling process to maintain healthy bone mass and growth. Metabolic bone diseases are a heterogeneous group of diseases caused by abnormalities of bone mass, mineral structure homeostasis, bone turnover, or bone growth. In pediatrics, several significant advances have been made in recent years in the diagnosis of metabolic bone diseases (e.g., osteogenesis imperfecta, hyperparathyroidism, rickets, renal osteodystrophy, pediatric osteoporosis, and osteopetrosis). Imaging is fundamental in the diagnosis of these pathologies.
MeSH term(s)	Bone Diseases/diagnostic imaging ; Bone Diseases, Metabolic/diagnostic imaging ; Child ; Humans ; Osteogenesis Imperfecta/diagnostic imaging ; Osteoporosis ; Pediatrics ; Rickets
Language	English
Publishing date	2021-05-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	1360919-1
ISSN	1098-898X ; 1089-7860
ISSN (online)	1098-898X
ISSN	1089-7860
DOI	10.1055/s-0040-1722566
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Influence of allergic status and nasal polyposis on long-term Benralizumab response in eosinophilic severe asthma.

Sposato, B / Ricci, A / Camiciottoli, G / Carpagnano, G E / Pelaia, C / Santus, P / Pelaia, G / Palmiero, G / Di Tomassi, M / Ronchi, M C / Cameli, P / Bargagli, E / Ciambellotti, L / Rizzello, S / Sglavo, R / Coppola, A / Lacerenza, L G / Gabriele, M / Radovanovic, D /

Perrella, A / Rogliani, P / Scalese, M

La Clinica terapeutica

2023 Volume 174, Issue 1, Page(s) 67–74

Abstract: Objective: It is unclear whether Benralizumab effectiveness in severe eosinophilic asthma can be influenced by nasal polyposis (NP) or allergic status associations. We evaluated whether Benralizumab long-term efficacy in asthma outcomes could be ... ...

Abstract	Objective: It is unclear whether Benralizumab effectiveness in severe eosinophilic asthma can be influenced by nasal polyposis (NP) or allergic status associations. We evaluated whether Benralizumab long-term efficacy in asthma outcomes could be different in subjects with atopy (SAEA) compared to the effectiveness in those without allergies (SNAEA) and in individuals with NP compared to those without NP. Methods: This observational retrospective study considered 95 consecutive patients divided into allergic (SAEA; n:65[68.4%]; skin prick tests positive [SPT] and/or IgE values ≥100 UI/mL), and non-allergic (SNAEA; n:30[31.6%], SPT negative and normal IgE levels<100 UI/mL). Overall population was also divided into two groups according to NP presence (NP+:39[41%] and NP-:56[59%]). Benralizumab treatment mean was19.7±7.2 months (range 12-35). Results: No differences in Benralizumab effectiveness were found in asthma outcomes in patients with/without NP. SNOT-22 improvement was higher in NP+ (-22±24) compared to NP- groups (6.33±15.5;p=0.055). FEV1 (16.33±19.22%), ACT(7.45±3.95) increases and frequency of SABA use (3.37±4.99) reduction were higher in SAEA compared to what obtained in non-allergic subjects (FEV1:8.15±15.6%,p=0.043; ACT:4.89±3.57,p=0.005; SABA use:-1.16±1.84;p=0.015). 93.8% of SAEA patients whereas only 72.2% of SNAEA individuals reduced OC doses at least half after Benralizumab (p=0.035). These results were partially confirmed by linear regression models showing associations between allergic status and FEV1, ACT and SABA use changes (β=8.37;p=0.048, β=2.056;p=0.033 and β=-2.184;p=0.042 respectively). Conclusion: Benralizumab effectiveness in asthma appears to be independent of NP presence. The allergic eosinophilic disease, compared to just eosinophilic asthma, may be a more severe phenotype. Benralizumab may have greater efficacy in SAEA on some outcomes.
MeSH term(s)	Humans ; Anti-Asthmatic Agents/therapeutic use ; Eosinophils ; Retrospective Studies ; Asthma/complications ; Asthma/drug therapy ; Immunoglobulin E
Chemical Substances	benralizumab (71492GE1FX) ; Anti-Asthmatic Agents ; Immunoglobulin E (37341-29-0)
Language	English
Publishing date	2023-01-19
Publishing country	Italy
Document type	Observational Study
ZDB-ID	123320-8
ISSN	1972-6007 ; 0009-9074
ISSN (online)	1972-6007
ISSN	0009-9074
DOI	10.7417/CT.2023.2499
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 98: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with Benralizumab.

Buonamico, E / Dragonieri, S / Sciancalepore, P I / Carratù, P / Carpagnano, G E / Resta, O / Gelardi, M

Journal of biological regulators and homeostatic agents

2020 Volume 34, Issue 6, Page(s) 2353–2357

MeSH term(s)	Anti-Asthmatic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Eosinophilia ; Eosinophils ; Humans ; Inflammation
Chemical Substances	Anti-Asthmatic Agents ; Antibodies, Monoclonal, Humanized ; benralizumab (71492GE1FX)
Language	English
Publishing date	2020-12-28
Publishing country	Italy
Document type	Letter
ZDB-ID	639196-5
ISSN	1724-6083 ; 0393-974X
ISSN (online)	1724-6083
ISSN	0393-974X
DOI	10.23812/20-323-L
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2270: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study.

Quaranta, Vitaliano Nicola / Dragonieri, Silvano / Vulpi, Maria Rosaria / Crimi, Nunzio / Crimi, Claudia / Santus, Pierachille / Menzella, Francesco / Pelaia, Corrado / Scioscia, Giulia / Caruso, Cristiano / Bargagli, Elena / Scichilone, Nicola / Carpagnano, Giovanna Elisiana

Journal of clinical medicine

2023 Volume 12, Issue 1

Abstract: Background. Severe asthma and bronchiectasis are heterogeneous diseases that frequently coexist. The location of bronchiectasis is generally determined by specific underlying pathophysiological mechanisms. The aim of this study was to determine whether ... ...

Abstract	Background. Severe asthma and bronchiectasis are heterogeneous diseases that frequently coexist. The location of bronchiectasis is generally determined by specific underlying pathophysiological mechanisms. The aim of this study was to determine whether in a population suffering from both severe asthma and bronchiectasis there was a correlation between eosinophilic inflammation and localization of bronchiectasis. Methods. We enrolled 41 patients with coexisting bronchiectasis from eight different severe asthma center outpatient clinics and collected the following data: baseline characteristics, Asthma Control Test, Asthma Control Questionnaire, IgE level, blood count, high-resolution computed tomography and bronchiectasis-related parameters, skin prick test, FeNO50 and flow-volume spirometry. The study was retrospectively registered. Results. The presence of eosinophils > 1000 cells/μL was related to distribution of lower pulmonary bronchiectasis (9.1% upper lobes vs. 53.3% lower lobes, p = 0.014). Indeed, the presence of eosinophilic counts > 1000 increased the probability of lower localization of bronchiectasis compared to upper lobes (ODD 0.088 (0.010−0.772), p = 0.028). Conclusions. An increase in blood eosinophils > 1000 cells/μL seems to be associated with lower preferential localization of bronchiectasis with sparing of the upper lung lobes. This could represent a new potential radiological phenotype that could have a dedicated therapeutic strategy in the future.
Language	English
Publishing date	2023-01-03
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12010380
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Omalizumab as add-on therapy in a patient with severe asthma and OSA.

Scioscia, Giulia / Buonamico, Enrico / Foschino Barbaro, Maria Pia / Lacedonia, Donato / Sabato, Roberto / Carpagnano, Giovanna Elisiana

Respirology case reports

2020 Volume 8, Issue 2, Page(s) e0518

Abstract: Obstructive sleep apnoea (OSA) syndrome, the most frequent sleep-disordered breathing, is a comorbidity of asthma, whose prevalence covers about 49.5% of asthmatic adult patients. A 61-year-old female patient, affected by severe allergic asthma and ... ...

Abstract	Obstructive sleep apnoea (OSA) syndrome, the most frequent sleep-disordered breathing, is a comorbidity of asthma, whose prevalence covers about 49.5% of asthmatic adult patients. A 61-year-old female patient, affected by severe allergic asthma and obesity, started treatment with omalizumab and underwent polysomnography showing a severe OSA pattern (apnoea/hypopnoea index (AHI): 72.7). After six months, she showed functional improvement and good asthma symptoms control and underwent a new polygraphy for the persistence of the night symptoms which showed an ameliorated, despite still severe, OSA pattern (AHI: 31.9). The patient obtained complete polygraphic normalization after adequate positive airway pressure (PAP) titration. While bronchodilator efficacy in chronic obstructive pulmonary disease (COPD)/OSA overlap syndrome has been proven in raising nocturnal oxygen saturation, there is no such evidence about biological therapy in patients affected by severe asthma and OSA. This is the first documented case report that demonstrates a possible role of omalizumab in improving the OSA pattern in a patient affected by severe asthma and OSA.
Language	English
Publishing date	2020-02-07
Publishing country	United States
Document type	Case Reports
ZDB-ID	2750180-2
ISSN	2051-3380
ISSN	2051-3380
DOI	10.1002/rcr2.518
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito